Date: 2015-06-29
Type of information: Construction of new premises
Compound:
Company: Abbvie (USA - IL)
Therapeutic area: Autoimmune diseases - Medical devices
Type agreement: construction of new premises
Action mechanism:
Disease:
Details: * On June 29, 2015, AbbVie announced it will further expand its medical device manufacturing facility in Ballytivnan, Sligo, Ireland, and over the next four years, create 50 new highly-skilled jobs focused on devices that deliver AbbVie’s medicines to patients around the world. The investment is supported by the Industrial Development Authority (IDA) of Ireland and was announced at an event attended by the Minister for Jobs, Enterprise and Employment, Richard Bruton, TD. This announcement marks continued manufacturing investment by AbbVie in Ireland. Including this announcement, AbbVie’s investment in Ballytivnan and broader manufacturing operations in the country has reached a total of more than €134 million since 2013, when it launched as an independent biopharmaceutical company. The company’s manufacturing site in Ballytivnan currently produces drug delivery devices, including a pen-style injector that is used by patients around the world who use AbbVie’s treatment indicated for a range of auto-immune conditions. The site is AbbVie’s ‘centre of excellence’ for medical device manufacture, precision engineering, plastics moulding and metrology (the theoretical and practical aspects of measurement). AbbVie’s development of a global medical device centre of excellence in Sligo is broadening the potential for the company’s local workforce. For example, AbbVie is partnering with the Institute of Technology, Sligo, which is establishing a new medical device-focused education program on its Sligo campus.
Financial terms:
Latest news:
